July 21, 2005 |
Genentech Inc. warned doctors of a potential anemia risk for users of its Raptiva psoriasis drug and updated earlier cautions about infections and a bleeding disorder. Two people had a form of anemia stemming from premature destruction of red blood cells during studies conducted to win Raptiva's U.S. approval in 2003, the South San Francisco-based company said in a letter to doctors posted on the Food and Drug Administration's website.
May 3, 2005 |
Swiss firm Roche Holding and partners Genentech Inc. of South San Francisco and OSI Pharmaceuticals Inc. of Melville, N.Y., have asked U.S. regulators to approve the lung cancer drug Tarceva to treat pancreatic cancer. The three companies submitted an application to the Food and Drug Administration for the new use after a study showed that the drug helped patients live longer when taken with chemotherapy, Roche said.
December 4, 2007 |
The Food and Drug Administration will ask outside experts Wednesday whether Genentech Inc.'s Avastin should be approved to treat breast cancer, despite mixed results in company studies. After reviewing the South San Francisco firm's data, the agency said patients on Avastin and chemotherapy had slower cancer progression but did not survive longer overall than patients on chemotherapy alone. Shares of Genentech fell $2.75, or 3.6%, to $73.50.
May 2, 2007 |
Genentech Inc. and Biogen Idec Inc. said their Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potential new way of treating the progressive neurological disease. The biotechnology companies said the Phase II trial involved 104 patients with the most common "relapsing-remitting" form of multiple sclerosis -- in which patients have varying levels of recovery and periods of remission between flare-ups of the autoimmune disease.
August 20, 2005 |
Genentech Inc. said that Mark Richmond would resign Oct. 31 from its board of directors and that energy executive Debra L. Reed became a member this week. Richmond, 74, a senior research fellow in science policy at the University College of London, has been a Genentech director since 1999. Reed is chief operating offer of Sempra Energy's San Diego Gas & Electric Co. and Southern California Gas Co.
December 2, 2004 |
Genentech Inc. has licensed antibody technology from Xencor Inc., a small biotechnology company in Monrovia, to develop next-generation versions of Genentech's cancer drugs Rituxan and Herceptin. Genentech, based in South San Francisco, will pay Xencor a $5-million fee and annual licensing fees. The smaller company is eligible for undisclosed milestone payments and royalties. Xencor is a Caltech spinoff working on drugs for rheumatoid arthritis and other diseases.
December 7, 2006 |
Insmed Inc. infringed three patents covering a treatment for abnormally short children, a jury said in a lawsuit brought by Genentech Inc. and Tercica Inc. The jury in federal court in Oakland awarded San Francisco-based Genentech and Brisbane, Calif.-based Tercica $7.5 million in damages and a percentage of future sales of the treatment. Richmond, Va.-based Insmed's Iplex and Tercica's product, called Increlex, are growth drugs used to treat about 6,000 short children.
June 2, 2004 |
Genentech Inc. and Alkermes Inc. said Tuesday that they would stop making Nutropin Depot, a long-acting treatment for growth hormone deficiency in children, in a move that Alkermes said would reduce its revenue for the year. The companies said it was too costly to continue making and marketing the product. Nutropin Depot, approved in 1999 by U.S. regulators, is a form of the human growth hormone somatropin.